Roche further taps drug discovery spinout's Nimble tech in $1.1B biobucks deal

Roche is making sure its peptide discovery spinout Nimble Therapeutics stays close with a revision of the companies’ development partnership valued at up to $1.1 billion.

The pharma's Genentech unit will pay out $20 million to Nimble upfront in the revamped collaboration, with up to $1.1 billion possible in near-term, preclinical, clinical, and commercial milestone payments, plus royalties.